Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03678350 · ClinicalTrials.gov registry record · Phase 1
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
A Phase 1 study of Non-Small-Cell Lung Carcinoma and Malignant Mesothelioma, sponsored by Roswell Park Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03678350: Active Phase 1 study of Non-Small-Cell Lung Carcinoma and Malignant Mesothelioma, sponsored by Roswell Park Cancer Institute.
NCT03678350 is a Phase 1 study of Non-Small-Cell Lung Carcinoma and Malignant Mesothelioma that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 9 participants, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03678350, a Phase 1 study of Non-Small-Cell Lung Carcinoma and Malignant Mesothelioma, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma , non-small cell lung cancer or any other malignancy with pleural disease undergoing surgery. Light dosimetry measures the amount of laser light given during photodynamic therapy. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to light. The activated drug may kill tumor cells. Using light dosimetry for intraoperative photodynamic therapy may help doctors estimate how much light is delivered during photodynamic therapy and decide if the treatment should be stopped or continued.
Primary Outcome
The frequency of toxicities will be tabulated by grade across all dose levels and cycles. All subjects who receive any study treatment will be considered evaluable for toxicity.
Conditions Studied
Interventions
- DEVICE Light Dosimetry for Intranoperative Therapy
- PROCEDURE Photodynamic Therapy
- DRUG Porfimer Sodium
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2026-10-13 |
| Phase | Phase 1 |
What the registry record for NCT03678350 still lists
NCT03678350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Light Dosimetry for Intranoperative Therapy is the first listed.
NCT03678350 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03678350 about?
NCT03678350 is a clinical study titled "Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery". This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma , non-small cell lung cancer or any other malignancy with pleural disease undergoing surgery. Light dosimetry me...
What is the current status of trial NCT03678350?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-09-17. Estimated completion is 2026-10-13.
What conditions does trial NCT03678350 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma, Malignant Mesothelioma, Pleural Disorder.
What interventions are being tested in trial NCT03678350?
The interventions under investigation include: Light Dosimetry for Intranoperative Therapy (DEVICE), Photodynamic Therapy (PROCEDURE), Porfimer Sodium (DRUG).
Who is sponsoring clinical trial NCT03678350?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03678350 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03678350's enrollment target sits among peer trials
9 31st of 30 the lowest of 30 other Non-Small-Cell Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small-Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
RECRUITING · Phase 1
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Retifanlimab and Ruxolitinib In Solid Malignancies
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RECRUITING · Phase 1
-
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
ACTIVE NOT RECRUITING · Phase 1
-
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI